หมวดหมู่: SeaPRwire

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order. As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients. The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026). Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster. As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2]. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval. The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. China Insights Consultancy’s industrial report  2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.  3. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 4. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 11, 2026 – (SeaPRwire) – HYVE Promo today announced the launch of its AI-enabled print-on-demand platform designed to modernize Asia-Pacific’s corporate gifting and branded merchandise industry. While e-commerce in Asia has produced multi-billion-dollar unicorns, the region’s corporate gifting supply chain remains largely manual — dependent on spreadsheets, fragmented factory coordination, and week-long quote cycles. HYVE enters the market as a technology-first infrastructure platform built to streamline customization, printing, and cross-border fulfillment at scale. HYVE positions itself as the corporate gifting equivalent of Asia’s major e-commerce platforms — purpose-built for businesses that need fast, reliable, and compliant branded merchandise delivered across multiple markets. “Asia built some of the world’s largest e-commerce engines,” said Tim Ngiam, General Manager of HYVE. “But the corporate merchandise industry hasn’t kept pace. We built HYVE to bring platform thinking, AI-driven workflows, and print-on-demand efficiency to a sector still operating like it’s 2005.” AI-Driven Merch Infrastructure HYVE combines: AI-assisted artwork processing and print optimization Real-time production routing across decoration technologies Automated order batching for small and mid-sized runs Cross-border logistics orchestration for APAC distribution The platform integrates directly with HYVE’s high-capacity production hub in Ningbo, China, capable of processing approximately 500 orders daily. Small-batch corporate orders can ship in as little as 72 hours, serving markets including Singapore, Japan, Korea, India, Southeast Asia, and Greater China. Rather than operating as a marketplace aggregator, HYVE controls the full print-to-ship workflow — reducing supplier handoffs and production errors. Targeting a Rapidly Digitizing Market The global promotional products market is projected to reach US$37 billion by 2033, while Asia-Pacific corporate gifting is expected to exceed US$400 billion within the same timeframe. More than 40% of buyers now expect to manage merchandise orders digitally — from proofing to tracking to fulfillment. HYVE aims to become what its founders call “Asia’s largest merch engine” — a centralized infrastructure layer for corporate gifting across the region. “Marketers and procurement teams want the same simplicity they get when ordering consumer products online,” said Ethan Ung, Co-Founder and Chief Commercial Officer. “They don’t want to manage factories, chase quotes, or coordinate customs. They want speed, visibility, and certainty. That’s what a platform should provide.” Built for Enterprise and Regional Scale HYVE focuses initially on APAC enterprise buyers and distributors, offering: On-demand production Regional multi-country fulfillment Compliance-ready manufacturing standards Rapid turnaround for campaign-driven activations The company plans to expand product categories, introduce deeper AI automation across artwork and routing, and integrate with marketing and e-commerce ecosystems used by enterprise teams. About HYVE Promo HYVE Promo is a Singapore-based technology platform modernizing corporate gifting across Asia-Pacific. Backed by the founders of BrandCharger and Headwind Group, HYVE operates a vertically integrated print and fulfillment engine designed to bring AI-driven efficiency, transparency, and scalability to branded merchandise distribution. For more information, visit: https://hyve.promo Media Contact Ming Yi Lim, Marketing Manager HYVE Promo Pte Ltd mingyi.lim@hyve.promo

SINGAPORE – March 09, 2026 – (SeaPRwire) – AI Labs, an AI-driven crypto trading technology company backed by Academic Labs, announced the launch of an AI-assisted platform designed to help cryptocurrency traders analyze market data and respond more efficiently to changing market conditions. As automated tools and algorithmic strategies become more common in global digital asset markets, the platform integrates visual analysis, narrative data monitoring, and automated trade execution features intended to support more structured and data-driven trading decisions. The fastest traders in today’s crypto markets may not always be humans. As digital asset markets increasingly incorporate automation, many traders now rely on algorithmic systems that can monitor markets continuously and react to signals with minimal delay. A crypto project called AI Labs (ticker: AIX) is building an AI-enabled platform that combines visual reasoning, narrative intelligence, and automated execution to help users interpret market data and respond to signals more efficiently than traditional manual analysis alone. “Markets are entering an era where the use of artificial intelligence is becoming more common in trading strategies,” said Kingston Kwek, owner of AI Labs. “Our goal is to make analytical tools that are often used by institutional trading teams more accessible to a wider group of crypto traders.” At the center of AI Labs’ platform is a visual reasoning engine that analyzes charts not simply as static images, but as evolving market structures. Using computer vision and multimodal AI techniques, the system can identify potential liquidity zones, resistance levels, and broader market patterns within short timeframes. Alongside this, AI Labs has developed a narrative intelligence layer that scans information across the crypto ecosystem. This includes movements associated with large crypto wallets, developer updates, and shifts in online sentiment—signals that traders often monitor when assessing possible market trends. Instead of only placing individual buy or sell orders, traders can define broader trading parameters using the AI system. The platform can then execute trades automatically based on predefined conditions, such as capital inflows, volatility changes, or funding-rate shifts. The objective is to help reduce emotional decision-making and allow traders to stay aligned with their strategies while automated systems monitor market activity continuously. AI Labs’ platform is currently onboarding new users, with reported monthly trading activity exceeding $1 billion across the platform. Media Contact Brand: AI Labs (Backed by Academic Labs) Contact: Media team Email: ryan@academic-labs.org Website: https://academic-labs.org

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 05, 2026 – (SeaPRwire) – Core Concepts Physio, one of Singapore’s leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain. Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved. To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked. A Smarter, More Complete Way to Diagnose Heel Pain Physiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support. The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in: More accurate, holistic diagnoses Fully optimised treatment strategies Fewer flare-ups and recurrences Clearer, consistent guidance for patients Faster and more sustainable outcomes “Many patients struggle because plantar fasciitis isn’t caused by just one issue,” said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. “It’s a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms.” A Case Study Demonstrating Collaborative Success In a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts. A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient’s daily load decreased significantly — allowing physiotherapy progress to continue without setbacks. Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running. “This case reflects what we see frequently,” said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. “Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery.” Making Multidisciplinary Care Accessible Nationwide Through this collaboration, patients with plantar fasciitis now benefit from: Joint physiotherapy–podiatry assessments Aligned clinical decision-making Consistent communication across providers A thorough evaluation of both the cause and consequence of heel pain A fully optimised recovery pathway “Our multidisciplinary team brings together the best of both professions,” said Mr Chng Chye Tuan. “Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands.” About Core Concepts Physiotherapy Core Concepts Physio is one of Singapore’s largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580. About Podiatry Quest Podiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care. Contact Details Organization: Core Concepts Pte Ltd Contact: Clemence Lim Email: marketing@coreconcepts.com.sg Website: https://www.coreconceptsphysio.sg

Base58 Labs Advances Integration of Proprietary BHLE Infrastructure LONDON, United Kingdom – March 04, 2026 – (SeaPRwire) – BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure. BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets. Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture. In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling. “Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.” BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants. With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026. About Base58 Labs Base58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/ Media Contact Base58 Labs PR Team Email: info@base58labs.com BASIS Official Website: https://basis.pro/ Base58 Labs Official Website: https://base58labs.com/

Tashkent, Uzbekistan – March 04, 2026 – (SeaPRwire) – FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium – a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework. Why Uzbekistan – Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter. Asterium’s project is designed to operate fully within this framework. What Was Deployed – FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium’s business model. The core deployment covers three key layers: Banking infrastructure – management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems. Digital asset infrastructure – crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan’s Mirasmanda ledger for HUMO asset support. Compliance and exchange – a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off. The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards – all within a regulated environment. How the Partnership Works – FinHarbor operates as Asterium’s strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion. “This project required deep architectural customization – from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards,” said Ilya Podoynitsyn, CEO of FinHarbor. “The core phase is complete, and we are already scaling the platform with new products and business use cases.”   What’s Next – With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform’s functionality to support additional business lines built on the deployed stack. About FinHarbor FinHarbor provides modular technology infrastructure for launching compliant financial products – from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets. Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Email: press@finharbor.com Website:  https://www.finharbor.com/

Hong Kong – March 02, 2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026. Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how. Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational. Governing AI in a Fragmented World On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI). The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes. Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third. The problem is not only detection. It is coordination under uncertainty. The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims. Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals. AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure. Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement. The Evidence Dilemma and the 2026 International AI Safety Report On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute. The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare. The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed. The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered. The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability. For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates. From Conversation to Capacity AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate. Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact. About AI Safety Asia AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement. AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up. Social Link LinkedIn: https://www.linkedin.com/company/ai-safety-asia/ Media Contact Brand: AI Safety Asia Contact: Media team Email: contact@aisafety.asia Website: https://www.aisafety.asia

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape.  According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge.  Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.”  The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time.  Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music.  Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone.  This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates.  About Dr. Don  Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression.  Media Contact  Dr. Don  E: don@drdonmusic.com  W: https://drdonmusic.com/

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my

New York, NY – February 01, 2026 – (SeaPRwire) – Recently, the world’s only Pokémon card graded PSA 10 – Pikachu Illustrator – once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment. Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory. The Legendary Status of the World’s Only PSA 10 According to publicly available information, the world’s only PSA 10 “Pikachu Illustrator” card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting. The Industry Significance of Goldin Auctions Although Logan Paul’s acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card’s contemporary circulation and visibility. As one of the world’s most influential high-end collectibles auction platforms, Goldin’s auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market. Netflix Documentary Captures a Cultural Moment Amid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference. Global Participation and TCG.Zone’s Involvement The discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand. Continuing to Follow the Card’s Future Trajectory In post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world’s only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value. The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting. Social Links Twitter: https://x.com/tcgzoneofficial Instagram: https://www.instagram.com/tcgzoneofficial/ Telegram: https://t.me/tcgzoneofficial Media Contact Brand : The Collectors Grid (tcg.zone) Contact: Annie Email: hi@tcg.zone Website: https://www.tcg.zone

SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Moscow, Russia – January 31, 2026 – (SeaPRwire) – Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead. Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise “The Third Rome” and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations. Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades. “By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society,” Oreshkin said. “Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives.” 1. A New Global Economic Paradigm: Globalisation 2.0 A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements. “Globalisation hasn’t ended; it has changed,” Oreshkin said. “Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world.” China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and “connector countries” like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy. 2. Platformisation and Institutional Automation The second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond. “Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms,” Oreshkin said. “Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts.” 3. Transformation of the Global Financial System It was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance. “The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system,” he said. 4. Demographic Shifts and Challenges The fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services. “Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%,” Oreshkin explained. “Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other.” 5. Human Capital Development in the Technological Era The final megatrend focuses on human capital in a rapidly changing technological environment. Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities. “AI is both a challenge and an opportunity,” Oreshkin said. “It allows personalized learning paths and supports teachers. Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era.” Global Perspective Throughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands. “The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future,” Oreshkin concluded. Open Dialogue on Air This year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna. First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually. Social Links Telegram: https://t.me/gowithrussia VK: https://vk.com/gowithrussia OK: https://ok.ru/gowithrussia DZen: https://dzen.ru/gowithrussia Contact for the media Brand: Russia National Centre Contact: Media team Email: Pressa@russia.ru Website: https://russia.ru Essay Submission: https://dialog.russia.ru/en/

In Collaboration with MAGO Moon Museum, Opening the “$VIVI RWA MARKET” Singapore – January 29, 2026 – (SeaPRwire) – LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the “$VIVI RWA MARKET,” a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY’s ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization. Digitalizing Humanity’s Masterpieces Through AI 3D Scanning Technology – A New Purchasing Experience Led by LEGENDARY HUMANITY LEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the “$VIVI RWA MARKET,” an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum “MAGO Moon Museum,” created by contemporary artist Shingo Nagasaka. This initiative forms part of the “VIVI PROJECT,” which aims to digitize humanity’s masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology. Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist’s worldview and creative philosophy. Overview Name: $VIVI RWA MARKET Opening Date: Thursday, January 29, 2026 URL: https://mondo.lhvivi.io/ About “$VIVI RWA MARKET” The “$VIVI RWA MARKET” is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum. Seamless Pathway from Viewing to Purchase Users can seamlessly transition from an artwork’s exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership. Integration of Physical and Digital Asset Design Each artwork includes the following structured information: Physical artwork details (size, materials, condition, provenance) High-resolution digital data generated through AI 3D scanning Artist profile and project background information along with other curated metadata. This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value. Ecosystem Holding Functionality Acquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks. About LEGENDARY HUMANITY and the VIVI PROJECT LEGENDARY HUMANITY promotes the “VIVI PROJECT,” which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of “Bringing the beauty of humanity to AI and the future.” Targeted assets include: Legendary fashion collections Historical architecture and cultural masterpieces Famous trading cards Artworks, including those exhibited at MAGO Moon Museum and other assets that can be described as humanity’s masterpieces. The VIVI PROJECT aims to: Digitize assets as digital cultural heritage Tokenize them as RWAs for global circulation Exhibit them in both online and physical museums thereby building new infrastructure that harmonizes cultural and economic value. NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.io RWA Market Roadmap The launch of the “$VIVI RWA MARKET” represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include: VIVI FASHION (RWA for the fashion domain) VIVI TRADING CARD (RWA for the trading card domain) VIVI ART WORK (RWA for art collections) with future integration under consideration. About MAGO Moon Museum MAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana. The museum provides an online space to view Nagasaka’s representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of “Sustainable Capitalism.” With the implementation of the “$VIVI RWA MARKET,” viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist’s philosophy in an appropriate and structured manner. Future Developments Building on this initiative, LEGENDARY HUMANITY plans to: Expand collaborations with masterpieces across different regions and genres Strengthen international networks with artists, collectors, and researchers Advance technological development for the preservation of cultural assets for future generations and continue developing as a platform that passes humanity’s masterpieces into the future through real-world assets. Media Contact Company Name: LEGENDARY HUMANITY PTE. LTD. Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953 Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations Desk Email: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io

Commences building an RWA (Real-World Asset) token economy Maximizing Value Through Digitalization Using Cutting-Edge 3D Scanning Technology “SCAI” and RWA Indexing New York, NY – January 20, 2026 – (SeaPRwire) – VIVI PROJECT (formerly LEGENDARY HUMANITY) announces a major update and rebranding. The project utilizes the latest 3D scanning technology “SCAI” to digitally archive humanity’s cultural heritage, providing training data for AI and building a new token economy based on RWA (Real World Assets). Background and Project Evolution Previously, “LEGENDARY HUMANITY” aimed to digitize humanity’s greatest masterpieces using cutting-edge technology, teaching AI about “humanity’s magnificence” to preserve its value for future generations. With this update, the project is renamed “VIVI PROJECT.” Moving beyond mere archiving, it will challenge the creation of new value in the Web3 era as an “RWA token project” building a unique economic ecosystem backed by real-world assets (RWA). The Four Pillars of the “RWA Ecosystem” Provided by VIVI PROJECT Digitization via High-Precision 3D Scanning Technology “SCAI:DIGITAL LUMINOUS Technology” Digitizing humanity’s treasures and providing them as AI training data. Merging human wisdom with technological evolution. Adding RWA Value to VIVI COiN: Centered around the project token “VIVI COiN,” we plan to link RWA held by collectors partnered with “VIVI PROJECT” to enhance the project’s value.By using “LEGENDARY masterpieces” whose value appreciates over time as the foundation for “VIVI COiN,” we build a stable value base. Hybrid Digital & Physical Museum Collected RWAs will be displayed in both digital museums and physical exhibition facilities. Trading via the marketplace will also be enabled, enhancing liquidity as an asset. VIVI DAO’s “Buy-Back & Burn” Model The governing body, “VIVI DAO,” will use exhibition and sales revenue to implement “Buy-Back” and “Burn” of VIVI COiN. This will increase the token’s scarcity and promote long-term value appreciation. Future Outlook: Global Collection Partnerships The VIVI PROJECT is advancing the networking of collections held by global asset owners. As a first step, we have initiated the following partnerships and negotiations: LA MUSEUM: Holds one of the world’s largest legendary fashion collections, including Yves Saint Laurent, Comme des Garçons, Worlds End, Alexander McQueen, John Galliano, and Madison Martin Margiela. Major Trading Card Company: Negotiations have commenced with the world’s largest trading asset company. This will integrate Real-World Assets (RWAs) from diverse genres like fashion, art, and hobbies into the project, rapidly expanding the ecosystem. VIVI PROJECT Overview VIVI PROJECT is a next-generation platform that preserves and utilizes humanity’s greatest masterpieces in both digital and physical realms through the fusion of culture and technology. By indexing RWA, it defines new asset value in the Web3 era. Official Website: https://lhvivi.com Contact for Inquiries Contact: VIVI PROJECT PR Department Email: press@lhvivi.com

Introduction Carrying Hope Building the Future Together Creative Pulse Group CPG with care for the Thai people and a strong commitment to social development hereby releases the White Paper Thailand Strategy 2026 to 2030. We believe that over the next four years CPG will work with all sectors of Thai society to deliver clear outcomes for the people and contribute to the development of Thailand. Company Overview Driven by Innovation Global Vision Creative Pulse Group CPG is a global advertising and brand communications company headquartered in the United States founded by advertising and communications expert Santiago Torres in 2009. CPG follows the principle of innovation driven excellence and uses creativity and future focused strategy to drive brand growth grow together with society and create sustainable shared value. Core Business Multi Dimensional Collaboration Creating Value Together Marketing strategy and brand positioning: Providing full brand positioning and communications strategy services across multiple industries and markets to enhance brand value. Integrated creative communications: Planning and producing advertising content and communications plans across digital and social media channels to maximize brand awareness. Precise audience reach: Using deep data analysis to reach target audiences accurately communicate effectively and improve conversion to marketing outcomes. Large scale public relations and promotion: Planning and executing public relations activities and partnership programs to strengthen brand awareness and influence in tangible ways. Global Network Systematic Coordination Seamless Connection CPG has built strategic structures across many countries and regions forming a network covering 28 countries with 115 offices worldwide to ensure efficient international coordination and deliver outstanding global services to clients. Thailand Strategy Local Insight Joint Development Remote workforce recruitment: Recruiting more than 3000000 Thai remote employees to create large scale job opportunities and help Thai people achieve economic self reliance. Regional branch setup: Establishing more than 1000 regional branches to localize operations in greater detail and serve the Thai market more effectively. Building a sustainable advertising platform: Creating a sustainable advertising platform encouraging broad participation in promotion and sharing building a growing advertising ecosystem that benefits many Thai people. Mission and Vision Social Responsibility Giving Back to the Country Precise advertising communication: Improving advertising effectiveness helping brands build influence in global markets achieve business goals and energize the Thai economy. Innovation and digital transformation: Embracing digital platforms and advanced technologies improving workflows increasing operational efficiency and supporting Thailands digital transformation. Closer connection with target audiences: Working closely with partners so communications content matches target audiences enabling effective communication and deep connection strengthening brand competitiveness in the Thai market. Creating sustainable jobs and entrepreneurship: Focusing on creating stable reliable job opportunities and driving entrepreneurial growth supporting long term prosperity for individuals and society and contributing to Thai social development Development Approach Steady Serious Long Term CPG emphasizes that the plan is not about rapid short term expansion but prioritizes long term sustainability. The main goal is to build a platform with clear structure stable operations repeatable processes and scalable growth laying a strong foundation for future steady development. Social Responsibility Gratitude Giving Back to Society CPG does not focus only on economic benefits but elevates social responsibility as a core strategic priority. We will promote charitable work in Thailand care for vulnerable groups and help build a harmonious society. We will also support local infrastructure development such as rail water resources and roads to promote sustainable social and economic development in local areas. Through close cooperation with government agencies educational institutions charitable organizations and social networks CPG aims to create inclusive growth opportunities for society. Ongoing public benefit activities to expand opportunities and improve quality of life Disaster and emergency relief: When disasters or emergencies occur provide timely support help communities overcome crises and deliver love and hope. Education support: Promote education development create learning opportunities for youth develop future talent and support Thai education. Employment support for vulnerable groups: Create more job opportunities with focus on supporting vulnerable groups promoting fairness and protecting basic rights building a harmonious society. Long term care mechanism and participation: Encourage continuous public participation in social activities generating long term positive outcomes building an ecosystem of good deeds with everyone involved and spreading care across Thailand. Thai Market Development Strategy Continuous Progress Steady and Far Reaching Short term 2025 to 2026: Large scale online recruitment plan: By 2025 complete the first round of recruitment and reach more than 900000 online members to build a foundation for further growth. Role expansion and skills training: In 2026 plan to add 1800000 job positions and continuously improve training systems and employee management while supporting skills and career courses so everyone can have more stable income and bring more benefits to communities. Long term 2027 to 2030: Expand local operating points and organizational development: Establish a system of core offices and collaboration in Thailand to provide a better work environment and drive continuous organizational growth and improvement toward sustainability. Build a new generation cultural community: Promote cultural exchange and integration build an energetic innovative community enrich spiritual life and support social harmony Promote education and scholarship programs: Create scholarship programs support capable Thai students provide opportunities for further study support Thai education and develop future leaders. Drive employment projects and key city development plans: Design area specific employment programs for key Thai cities promote local economies improve quality of life and support Thailands urban development process. Southeast Asia Expansion Based in Thailand Reaching the Region The company will expand across Southeast Asia with Thailand as the hub and extend to Malaysia the Philippines Singapore Cambodia Myanmar Laos and other countries in the region Based on a proven operating model the business will expand steadily enabling brand communications to reach deeper and farther while supporting Southeast Asian countries to upgrade their economies and grow together. Corporate Culture Diverse Inclusive Growing Together CPG promotes a culture of integrity equality and transparency respects diversity and does not discriminate by ethnicity religion or background. We believe diversity is a key force for innovation and growth. CPG aims to build a positive work environment where people receive fairer opportunities and improved quality of life. Conclusion Move Forward Together Create Shared Success CPG states that 2026 to 2030 is a key period when the company will move from steady development to a more complete system and a more stable structure. We will always uphold the principles of legal compliance transparency and stability. We will stand alongside employees partners and the market to grow together for long term sustainable development Our mission Support vulnerable groups through charity contribute to social development promote social progress build a harmonious society and pass on love in Thailand Our vision CPG is a responsible and trustworthy company We hope every employee will grow into a recognized leader and create long term value for the future of Thailand Our values At CPG we value everyone Employees are the main driving force of organizational development We value team diversity This is a family made of different skills backgrounds ethnicities genders and professions. We provide not only stable work but also multiple ways to increase income supporting everyone toward financial stability. We are a team with distinctive creativity working together on a special mission. CPG believes that in the next four years we will walk alongside the Thai people and build a brighter future together. Let us work together for a more prosperous Thailand tomorrow CEO: Santiago Torres LINE: @CPG555 facebook: https://www.facebook.com/CPG333 Tiktok:  https://www.tiktok.com/@cpg555.com Youtube: https://www.youtube.com/@CPG555 Email: CPGCreativePulseGroup@gmail.com Website : https://cloudrouge.com

1. บทนำแบกรับความหวังร่วมสร้างอนาคต Creative Pulse Group CPG ด้วยความห่วงใยต่อประชาชนไทยและความมุ่งมั่นต่อการพัฒนาสังคม จึงเผยแพร่ เอกสารไวท์เปเปอร์ยุทธศาสตร์ประเทศไทย 2026 ถึง 2030 เรามั่นใจว่าในช่วง 4 ปีข้างหน้า CPG จะร่วมมือกับทุกภาคส่วนของสังคมไทย เพื่อนำผลลัพธ์ที่ชัดเจนมาสู่ประชาชน และมีส่วนร่วมต่อการพัฒนาประเทศไทย 2. แนะนำบริษัทขับเคลื่อนด้วยนวัตกรรมมุมมองระดับโลก Creative Pulse Group CPG เป็นบริษัทโฆษณาและการสื่อสารแบรนด์ระดับโลก มีสำนักงานใหญ่ในสหรัฐอเมริกา ก่อตั้งโดยผู้เชี่ยวชาญด้านโฆษณาและการสื่อสาร Santiago Torres ในปี 2009 CPG ยึดแนวคิด ขับเคลื่อนด้วยนวัตกรรม สร้างความเป็นเลิศ มุ่งใช้ความคิดสร้างสรรค์และกลยุทธ์เชิงอนาคต เพื่อผลักดันการเติบโตของแบรนด์ เติบโตไปพร้อมกับสังคม และสร้างความยั่งยืนแบบเกื้อกูลร่วมกัน 3. ธุรกิจหลักประสานพลังหลากมิติร่วมสร้างคุณค่า กลยุทธ์การตลาดและการวางแบรนด์ ให้บริการกำหนดตำแหน่งแบรนด์และกลยุทธ์การสื่อสารอย่างครบถ้วน ครอบคลุมหลายอุตสาหกรรมและหลายตลาด เพื่อยกระดับมูลค่าแบรนด์ การสื่อสารเชิงสร้างสรรค์แบบบูรณาการ วางแผนและผลิตโฆษณา เนื้อหา และแผนการสื่อสาร ครอบคลุมสื่อดิจิทัลและโซเชียลมีเดียหลายช่องทาง เพื่อเพิ่มการรับรู้ของแบรนด์ให้สูงสุด การเข้าถึงกลุ่มเป้าหมายอย่างแม่นยำ อาศัยการวิเคราะห์ข้อมูลเชิงลึก เพื่อเข้าถึงกลุ่มเป้าหมายอย่างตรงจุดและสื่อสารได้มีประสิทธิภาพ เพิ่มอัตราการเปลี่ยนเป็นผลลัพธ์ทางการตลาด กิจกรรมประชาสัมพันธ์และการส่งเสริมการตลาดขนาดใหญ่ วางแผนและดำเนินกิจกรรมประชาสัมพันธ์และโครงการความร่วมมือ เพื่อยกระดับการรับรู้และอิทธิพลของแบรนด์อย่างเป็นรูปธรรม 4. เครือข่ายระดับโลกประสานงานเป็นระบบเชื่อมต่อไร้รอยต่อ CPG วางโครงสร้างเชิงกลยุทธ์ในหลายประเทศและหลายภูมิภาค สร้างเครือข่ายที่ครอบคลุม 28 ประเทศ และมีสำนักงานทั่วโลก 115 แห่ง เพื่อให้การประสานงานระดับสากลมีประสิทธิภาพ และมอบบริการระดับโลกที่ยอดเยี่ยมแก่ลูกค้า 5. ยุทธศาสตร์ประเทศไทยเจาะลึกท้องถิ่นร่วมพัฒนา การรับสมัครพนักงานทางไกล รับสมัครพนักงานทางไกลชาวไทยมากกว่า 3000000 คน เพื่อสร้างโอกาสงานจำนวนมาก ช่วยให้ประชาชนไทยพึ่งพาตนเองทางเศรษฐกิจ การจัดตั้งสาขาภูมิภาค จัดตั้งสาขาภูมิภาคมากกว่า 1000 แห่ง เพื่อให้การดำเนินงานมีความเป็นท้องถิ่นและละเอียดมากขึ้น และให้บริการตลาดไทยได้ดียิ่งขึ้น การสร้างแพลตฟอร์มโฆษณาที่ยั่งยืน สร้างแพลตฟอร์มโฆษณาที่ยั่งยืน สนับสนุนให้คนจำนวนมากเข้ามามีส่วนร่วมและขับเคลื่อนการโปรโมตและการแบ่งปัน สร้างระบบนิเวศโฆษณาที่เติบโต และเป็นประโยชน์ต่อประชาชนไทยจำนวนมาก 6. พันธกิจและวิสัยทัศน์รับผิดชอบต่อสังคมตอบแทนประเทศ การสื่อสารโฆษณาอย่างแม่นยำ ยกระดับประสิทธิภาพการสื่อสารโฆษณา ช่วยให้แบรนด์สร้างอิทธิพลในตลาดโลก บรรลุเป้าหมายทางธุรกิจ และเติมพลังให้เศรษฐกิจไทย นวัตกรรมและการเปลี่ยนผ่านสู่ดิจิทัล เปิดรับแพลตฟอร์มดิจิทัลและเทคโนโลยีล้ำสมัย ปรับปรุงกระบวนการทำงาน เพิ่มประสิทธิภาพการดำเนินงาน และสนับสนุนการเปลี่ยนผ่านสู่ดิจิทัลของไทย การสื่อสารกับกลุ่มเป้าหมายอย่างใกล้ชิด ทำงานร่วมกับพันธมิตรอย่างใกล้ชิด เพื่อให้เนื้อหาการสื่อสารสอดคล้องกับกลุ่มเป้าหมาย เกิดการสื่อสารที่มีประสิทธิผลและการเชื่อมต่อเชิงลึก เพิ่มความสามารถในการแข่งขันของแบรนด์ในตลาดไทย การสร้างโอกาสงานและผู้ประกอบการอย่างยั่งยืน มุ่งสร้างโอกาสงานที่มั่นคงเชื่อถือได้ และผลักดันการเติบโตของผู้ประกอบการ สนับสนุนความมั่งคั่งระยะยาวของบุคคลและสังคม และมีส่วนร่วมต่อการพัฒนาสังคมไทย 7. แนวทางการพัฒนามั่นคงเน้นความจริงจัง ยึดระยะยาว CPG ย้ำว่าแผนงานไม่ได้มุ่งขยายขนาดอย่างรวดเร็วในระยะสั้น แต่ให้ความสำคัญกับความยั่งยืนระยะยาว เป้าหมายหลักคือสร้างแพลตฟอร์มที่โครงสร้างชัดเจน การดำเนินงานมั่นคง สามารถทำซ้ำได้ และขยายได้ เพื่อวางรากฐานที่แข็งแรงสำหรับการพัฒนาอย่างมั่นคงในอนาคต 8. ความรับผิดชอบต่อสังคมสำนึกคุณตอบแทนสังคม CPG ไม่ได้มองเพียงผลประโยชน์ทางเศรษฐกิจ แต่ยกระดับการทำความรับผิดชอบต่อสังคมเป็นยุทธศาสตร์หลัก เราจะผลักดันงานการกุศลในประเทศไทย ดูแลกลุ่มเปราะบาง และมีส่วนร่วมสร้างสังคมที่กลมเกลียว พร้อมทั้งมีส่วนร่วมสนับสนุนการพัฒนาโครงสร้างพื้นฐานของเมือง เช่น รถไฟ แหล่งน้ำ ถนน เพื่อสนับสนุนการพัฒนาสังคมและเศรษฐกิจในท้องถิ่นอย่างยั่งยืน ด้วยความร่วมมืออย่างใกล้ชิดกับหน่วยงานรัฐ สถาบันการศึกษา องค์กรการกุศล และเครือข่ายสังคม CPG มุ่งสร้างโอกาสที่ครอบคลุมและเอื้อต่อการเติบโตให้กับสังคม การดำเนินกิจกรรมสาธารณประโยชน์อย่างต่อเนื่อง เพื่อเพิ่มโอกาสและยกระดับคุณภาพชีวิต การช่วยเหลือฉุกเฉินจากภัยพิบัติ เมื่อเกิดภัยพิบัติหรือเหตุฉุกเฉิน จะให้ความช่วยเหลืออย่างทันท่วงที สนับสนุนชุมชนให้ผ่านวิกฤต และส่งต่อความรักและความหวัง การสนับสนุนด้านการศึกษา ร่วมผลักดันการพัฒนาการศึกษา สร้างโอกาสการเรียนรู้ให้เยาวชน พัฒนาบุคลากรแห่งอนาคต และสนับสนุนการศึกษาของไทย การสนับสนุนการจ้างงานของกลุ่มเปราะบาง สร้างโอกาสงานเพิ่มขึ้น โดยให้ความสำคัญกับการสนับสนุนกลุ่มเปราะบาง ส่งเสริมความเป็นธรรมและการคุ้มครองสิทธิขั้นพื้นฐาน สร้างสังคมที่กลมเกลียว กลไกการดูแลระยะยาวและการมีส่วนร่วม สนับสนุนให้ผู้คนมีส่วนร่วมในกิจกรรมเพื่อสังคมอย่างต่อเนื่อง เกิดผลลัพธ์เชิงบวกในระยะยาว สร้างระบบนิเวศการทำความดีที่ทุกคนมีส่วนร่วม และส่งต่อความห่วงใยไปทั่วผืนแผ่นดินไทย 9. ยุทธศาสตร์การพัฒนาตลาดไทยเดินหน้าต่อเนื่องมั่นคงและไกล ระยะสั้น 2025 ถึง 2026 แผนรับสมัครออนไลน์ขนาดใหญ่ ภายในปี 2025 จะดำเนินการรับสมัครรอบแรกให้เสร็จสิ้น และมีสมาชิกออนไลน์เกิน 900000 คน เพื่อวางรากฐานสำหรับการเติบโตต่อไป การขยายตำแหน่งงานและการฝึกทักษะ ในปี 2026 วางแผนเพิ่มตำแหน่งงาน 1800000 ตำแหน่ง และพัฒนาระบบการฝึกอบรมและการบริหารพนักงานอย่างต่อเนื่อง พร้อมสนับสนุนหลักสูตรทักษะและอาชีพ เพื่อให้ทุกคนมีรายได้มั่นคงยิ่งขึ้น และเกิดประโยชน์ต่อชุมชนมากขึ้น ระยะยาว 2027 ถึง 2030 ขยายจุดดำเนินงานท้องถิ่นและพัฒนาองค์กร จัดตั้งระบบสำนักงานหลักและการทำงานร่วมกันในประเทศไทย เพื่อมอบสภาพแวดล้อมการทำงานที่ดีขึ้น และขับเคลื่อนการเติบโตและการปรับปรุงองค์กรอย่างต่อเนื่อง สู่ความยั่งยืน สร้างชุมชนวัฒนธรรมรุ่นใหม่ ส่งเสริมการแลกเปลี่ยนและการหลอมรวมทางวัฒนธรรม สร้างชุมชนที่มีพลังและนวัตกรรม เติมเต็มชีวิตจิตใจ และสนับสนุนความกลมเกลียวของสังคม ส่งเสริมการศึกษาและโครงการทุนการศึกษา จัดตั้งโครงการทุนการศึกษา สนับสนุนนักเรียนไทยที่มีศักยภาพ ให้โอกาสศึกษาต่อ สนับสนุนการศึกษาของไทย และพัฒนาผู้นำแห่งอนาคต ผลักดันโครงการจ้างงานและแผนพัฒนาเมืองสำคัญ ออกแบบโครงการจ้างงานเฉพาะพื้นที่สำหรับเมืองสำคัญของไทย ส่งเสริมเศรษฐกิจท้องถิ่น ยกระดับคุณภาพชีวิต และสนับสนุนกระบวนการพัฒนาเมืองของไทย 10. การขยายตลาดเอเชียตะวันออกเฉียงใต้ตั้งฐานที่ไทยกระจายสู่ภูมิภาค บริษัทจะมุ่งขยายตลาดเอเชียตะวันออกเฉียงใต้ โดยมีประเทศไทยเป็นศูนย์กลาง และขยายสู่มาเลเซีย ฟิลิปปินส์ สิงคโปร์ กัมพูชา เมียนมา ลาว และประเทศอื่นในภูมิภาค บนพื้นฐานของรูปแบบการดำเนินงานที่ผ่านการพิสูจน์แล้ว จะขยายธุรกิจอย่างมั่นคง ทำให้การสื่อสารของแบรนด์ต่างๆ เข้าถึงได้ลึกและไกลขึ้น พร้อมสนับสนุนให้ประเทศในเอเชียตะวันออกเฉียงใต้ยกระดับเศรษฐกิจและเติบโตร่วมกัน 11. วัฒนธรรมองค์กรหลากหลายครอบคลุม เติบโตไปด้วยกัน CPG ส่งเสริมวัฒนธรรมองค์กรที่ยึดความซื่อสัตย์ ความเท่าเทียม และความโปร่งใส เคารพความหลากหลาย ไม่แบ่งแยกตามเชื้อชาติ ศาสนา หรือพื้นหลัง เรามั่นใจว่าความหลากหลายคือพลังสำคัญของนวัตกรรมและการเติบโต CPG มุ่งสร้างสภาพแวดล้อมการทำงานเชิงบวก ให้ผู้คนได้รับโอกาสที่เป็นธรรมมากขึ้น และยกระดับคุณภาพชีวิต 12. บทสรุปก้าวไปด้วยกันสร้างความสำเร็จร่วมกัน CPG ระบุว่า ช่วงปี 2026 ถึง 2030 เป็นช่วงสำคัญที่บริษัทจะก้าวจากการพัฒนาอย่างมั่นคง ไปสู่ระบบที่สมบูรณ์ยิ่งขึ้น และโครงสร้างที่มั่นคงยิ่งขึ้น เราจะยึดมั่นในหลักการ “ถูกต้องตามกฎหมาย โปร่งใส และมั่นคง” เสมอ พร้อมเดินเคียงข้างพนักงาน พันธมิตร และตลาด เติบโตไปด้วยกัน เพื่อการพัฒนาที่ยั่งยืนในระยะยาวค่ะ พันธกิจของเรา ช่วยเหลือกลุ่มเปราะบางผ่านงานการกุศล มีส่วนร่วมต่อการพัฒนาสังคม ผลักดันความก้าวหน้าของสังคม สร้างสังคมที่กลมเกลียว และส่งต่อความรักในประเทศไทย วิสัยทัศน์ของเรา CPG เป็นบริษัทที่มีความรับผิดชอบและน่าเชื่อถือ เราหวังให้พนักงานทุกคนเติบโตเป็นผู้นำที่ได้รับการยอมรับ และสร้างคุณค่าระยะยาวในอนาคต เพื่อประเทศไทย ค่านิยมของเรา ที่ CPG เราให้ความสำคัญกับทุกคน พนักงานคือพลังขับเคลื่อนหลักของการพัฒนาองค์กร เราให้คุณค่ากับความหลากหลายของทีม นี่คือครอบครัวที่ประกอบด้วยทักษะ พื้นหลัง เชื้อชาติ เพศ และอาชีพที่แตกต่างกัน เราไม่เพียงมอบงานที่มั่นคง แต่ยังมีหลายช่องทางในการเพิ่มรายได้ สนับสนุนให้ทุกคนมุ่งสู่ความมั่นคงทางการเงิน เราเป็นทีมที่มีเอกลักษณ์และความคิดสร้างสรรค์ ร่วมกันสร้างภารกิจที่พิเศษ CPG เชื่อมั่นว่า ในอีก 4 ปีข้างหน้า เราจะเดินเคียงข้างประชาชนไทย ร่วมกันสร้างอนาคตที่รุ่งโรจน์ไปด้วยกันค่ะ มาร่วมแรงร่วมใจกันทำงาน เพื่อวันพรุ่งนี้ที่ประเทศไทยเจริญรุ่งเรืองยิ่งขึ้นนะคะ ผู้ติดต่อ Santiago Torres LINE: @CPG555 facebook: https://www.facebook.com/CPG333 Tiktok:  https://www.tiktok.com/@cpg555.com Youtube: https://www.youtube.com/@CPG555 อีเมล: CPGCreativePulseGroup@gmail.com เว็บไซต์ : https://cloudrouge.com/

Mexico City, Mexico – January 10, 2026 – (SeaPRwire) – Excent Capital has announced the launch of a new incentive program for its global partner network, offering exclusive experiences connected to the 2026 World Cu as part of its ongoing commitment to long-term collaboration and partner engagement. The initiative is designed to recognise partner performance and strengthen relationships through experiences that go beyond traditional rewards. Depending on performance tiers, partners may qualify for packages that include match tickets, travel arrangements, accommodation, and curated experiences in the United States during the tournament. Rather than focusing solely on volume, the program is structured to encourage sustainable growth, strategic alignment, and continued collaboration between Excent Capital and its partners. The incentive tiers are linked to clearly defined performance benchmarks, ensuring transparency and consistency across regions. “We work very closely with our partners on a daily basis, and this initiative is a way to give something back that goes beyond numbers,” said Andrés Espinosa, Senior Business Development Manager at Excent Capital. The World Cup 2026 incentive program is open to eligible partners worldwide and will run until May 15. Participation details, performance criteria, and tier qualifications are communicated directly to partners through Excent Capital’s regional business development teams. About Excent Capital Excent Capital is a global trading broker offering access to a wide range of financial markets. Operating on proprietary, in-house developed technology, the company focuses on transparency, execution quality, and partner-driven growth, supporting partners through education, consistent market insight, and collaborative initiatives. Contact Information Organization: Excent Capital Contact Person: Ryccielli Ongaratto, Marketing Manager Email: support@excent.capital Website: https://excent.capital/

ยึดหลักการพัฒนาในระยะยาวเป็นแกนหลัก ก้าวสู่ยุคใหม่ของการเติบโตที่มีคุณภาพและการพัฒนาเชิงภูมิภาค เมื่อไม่นานมานี้ PGM ได้ประกาศต่อสาธารณชนอย่างเป็นทางการถึง กลยุทธ์การพัฒนาปี 2026 และ แผนพัฒนาระยะกลางถึงระยะยาวสำหรับปี 2027–2028 ภายใต้บริบทที่เศรษฐกิจดิจิทัลทั่วโลกยังคงพัฒนาอย่างต่อเนื่อง และโครงสร้างองค์กรมีการยกระดับอยู่ตลอดเวลา PGM จะยึดแนวคิดการพัฒนาโดยมี “ความมั่นคง ความถูกต้องตามกฎหมาย และการมุ่งเน้นระยะยาว” เป็นแกนหลัก เพื่อขับเคลื่อนการยกระดับองค์กร การพัฒนาระบบ และการขยายเชิงภูมิภาคอย่างรอบด้าน วางรากฐานที่แข็งแกร่งสำหรับการเติบโตอย่างต่อเนื่องในอนาคต PGM ระบุว่า แผนการพัฒนาครั้งนี้ไม่ได้มุ่งเน้นการขยายขนาดในระยะสั้น แต่ให้ความสำคัญกับ การพัฒนาอย่างยั่งยืนในระยะยาว โดยมุ่งสร้างแพลตฟอร์มที่มี โครงสร้างชัดเจน การดำเนินงานมีเสถียรภาพ และสามารถนำไปขยายหรือทำซ้ำได้ อย่างเป็นระบบ 1. กลยุทธ์การพัฒนา ปี 2026: วางรากฐานให้มั่นคง ยกระดับคุณภาพ ปี 2026 จะถูกมองว่าเป็น “ปีแห่งการวางรากฐานสำคัญ” ของการพัฒนา PGM โดยบริษัทจะเดินหน้าดำเนินงานอย่างมั่นคงภายใต้ 4 แนวทางเชิงกลยุทธ์หลัก ดังต่อไปนี้: (1) ยกระดับโครงสร้างองค์กร เสริมสร้างศักยภาพด้านการบริหาร PGM จะเดินหน้าปรับปรุงโครงสร้างองค์กรและการแบ่งหน้าที่ความรับผิดชอบอย่างต่อเนื่อง พัฒนาระบบการเลื่อนตำแหน่งและการบ่มเพาะผู้บริหาร โดยมุ่งเน้นการยกระดับความสามารถของผู้บริหารระดับกลางและระดับสูง เพื่อสร้างโครงสร้างทีมงานที่มีเสถียรภาพและยั่งยืนมากยิ่งขึ้น (2) เสริมความแข็งแกร่งด้านการปฏิบัติตามกฎระเบียบและการบริหารความเสี่ยงอย่างรอบด้าน ในด้านการดำเนินงานที่ถูกต้องตามกฎหมาย PGM จะยกระดับความโปร่งใสทางการเงิน ระบบตรวจสอบภายใน และศักยภาพด้านการควบคุมความเสี่ยงของระบบ พร้อมทั้งเสริมสร้างความปลอดภัยของข้อมูลและการบริหารบัญชีอย่างต่อเนื่อง เพื่อยืนยันและตอกย้ำจุดยืนของตลาดในฐานะ “ตำแหน่งงานที่เป็นทางการ การดำเนินงานที่ถูกต้องตามกฎหมาย และการพัฒนาในระยะยาว” (3) ยกระดับระบบและศักยภาพด้านเทคโนโลยี PGM มีแผนดำเนินการอัปเกรดระบบหลายด้านภายในปี 2026 ครอบคลุมถึงการทำงานอัตโนมัติของกระบวนการดำเนินงาน การพัฒนาระบบสถิติข้อมูล และการปรับปรุงการคำนวณผลการปฏิบัติงาน เพื่อสร้างโครงสร้างพื้นฐานทางเทคโนโลยีที่มีเสถียรภาพและประสิทธิภาพ รองรับการขยายตัวในระดับขนาดใหญ่และการพัฒนาข้ามภูมิภาคในอนาคต (4) การสร้างแบรนด์และการสื่อสารเชิงบวกกับตลาด ผ่านการกำหนดแนวทางการสื่อสารภายนอกอย่างเป็นเอกภาพ และการเสริมสร้างการสื่อสารผ่านสื่อหลักและแพลตฟอร์มโซเชียลมีเดีย PGM จะยกระดับความน่าเชื่อถือของแบรนด์อย่างต่อเนื่อง และสร้างภาพลักษณ์องค์กรในฐานะ “องค์กรที่มั่นคง เป็นมืออาชีพ และเชื่อถือได้” 2. แผนพัฒนาระยะกลางถึงระยะยาว ปี 2027–2028: เจาะลึกตลาดเอเชียตะวันออกเฉียงใต้ เดินหน้าการขยายขนาดและการพัฒนาเชิงภูมิภาคควบคู่กัน หลังจากการวางรากฐานระบบต่าง ๆ เสร็จสมบูรณ์ในปี 2026 แล้ว PGM จะก้าวเข้าสู่ช่วงเร่งการพัฒนา เชิงขนาดและเชิงภูมิภาคโดยมีเอเชียตะวันออกเฉียงใต้เป็นศูนย์กลาง อย่างเป็นทางการในช่วงปี 2027–2028 บริษัทจะมุ่งเน้นการขยายตลาดในภูมิภาคเอเชียตะวันออกเฉียงใต้ โดยเฉพาะ ประเทศไทยและเมียนมา และดำเนินการขยายพื้นที่อย่างมั่นคงบนพื้นฐานของโมเดลการดำเนินงานที่มีความพร้อมและผ่านการพิสูจน์แล้ว ปี 2027: การพัฒนาเชิงขนาดอย่างมั่นคง ขยายขนาดทีมงานอย่างต่อเนื่องในตลาดที่มีความพร้อม พัฒนาผู้นำท้องถิ่นที่มีศักยภาพในการบริหารจัดการอย่างอิสระและสามารถถ่ายทอดรูปแบบการดำเนินงานได้ ยกระดับประสิทธิภาพการดำเนินงานโดยรวม ประสิทธิภาพต่อบุคลากร และความมั่นคงของทีมงาน ปี 2028: ผลักดันการพัฒนาเชิงภูมิภาคและการทำงานร่วมกัน ค่อย ๆ ดำเนินการขยายรูปแบบการดำเนินงานไปยังภูมิภาคอื่นบนพื้นฐานของโมเดลที่มีความพร้อม สร้างระบบการบริหารจัดการและการทำงานร่วมกันข้ามภูมิภาค พัฒนาระบบการดำเนินงานหลายภูมิภาคที่มีความยั่งยืนในระยะยาว PGM ระบุว่า การพัฒนาเชิงภูมิภาคจะยึดหลัก “ค่อยเป็นค่อยไป และควบคุมความเสี่ยงได้” เป็นเงื่อนไขสำคัญ เพื่อให้มั่นใจว่าทุกขั้นตอนของการขยายตัวจะตั้งอยู่บนระบบที่มีความสมบูรณ์และมีเสถียรภาพ 3. การขับเคลื่อนการพัฒนาเชิงท้องถิ่นในประเทศไทย: เร่งจัดตั้งระบบความร่วมมือด้านโฆษณา จากการที่ความร่วมมือกับ แบรนด์ท้องถิ่นในประเทศไทยเพิ่มขึ้นอย่างต่อเนื่อง ความต้องการด้านการประสานงานโฆษณาและความร่วมมือทางธุรกิจของแพลตฟอร์มจึงมีความชัดเจนมากยิ่งขึ้น ภายใต้แนวโน้มดังกล่าว PGM กำลังดำเนินการตามแผนอย่างเป็นขั้นตอน เพื่อจัดตั้ง ฝ่ายพัฒนาธุรกิจและความร่วมมือด้านโฆษณา ของบริษัทสาขาในประเทศไทย โดยให้ความสำคัญกับการวางแผนระยะเริ่มต้นใน อาคารสำนักงานย่านธุรกิจของกรุงเทพมหานคร ปัจจุบัน แผนงานที่เกี่ยวข้องได้เข้าสู่ ขั้นตอนการเตรียมการ ซึ่งครอบคลุมถึง การวางแผนสภาพแวดล้อมและพื้นที่สำนักงาน การประเมินโครงสร้างและการจัดสรรบุคลากร การปรับปรุงและเชื่อมต่อกระบวนการดำเนินงานด้านโฆษณาให้สอดคล้องกับระบบแพลตฟอร์ม หากการดำเนินงานโดยรวมเป็นไปอย่างราบรื่น คาดว่าจะสามารถ เริ่มเข้าพื้นที่และเปิดดำเนินงานในระยะแรกได้ภายในระยะเวลาประมาณหนึ่งเดือน เพื่อยกระดับประสิทธิภาพในการเชื่อมต่อกับแบรนด์ท้องถิ่นและทรัพยากรความร่วมมือทางธุรกิจในประเทศไทย บริษัทจะดำเนินการพัฒนาและปรับปรุงแผนงานในระยะถัดไปอย่างมั่นคงตามสถานการณ์จริง พร้อมทั้งเตรียมความพร้อมล่วงหน้าสำหรับ การจัดตั้งและการเข้าใช้อาคารสำนักงานอิสระของ PGM ประเทศไทยในอนาคต PGM ยังคงยึดมั่นในหลักการพัฒนา “วางแผนก่อนดำเนินการจริง ให้ความสำคัญกับระยะยาว และเน้นความมั่นคง” เพื่อให้ทุกขั้นตอนของการขยายตัวมีคุณค่าและความยั่งยืนในระยะยาว 4. แนวคิดการพัฒนาในระยะยาวโดยยึด “บุคลากร” เป็นศูนย์กลาง PGM ยึดมั่นมาโดยตลอดว่า การเติบโตในระยะยาวของพนักงาน คือขีดความสามารถในการแข่งขันที่สำคัญที่สุดขององค์กร ในช่วง สามปีข้างหน้า บริษัทจะเดินหน้าลงทุนทรัพยากรอย่างต่อเนื่องในด้าน การพัฒนาบุคลากรและผู้บริหาร การสร้างระบบแรงจูงใจในระยะยาว การออกแบบโครงสร้างรายได้ที่หลากหลายและยั่งยืน เพื่อมอบเส้นทางการพัฒนาอาชีพที่ ชัดเจน มีเสถียรภาพ และสามารถคาดการณ์ได้ ให้แก่พนักงานทุกคน พร้อมส่งเสริมให้เกิดวงจรการเติบโตเชิงบวกระหว่างการพัฒนาของบุคลากรและการเติบโตของแพลตฟอร์ม 5. การปฏิบัติความรับผิดชอบต่อสังคม: ตอบแทนสังคมด้วยกิจกรรมสาธารณประโยชน์ในระยะยาว ควบคู่ไปกับการขับเคลื่อนการพัฒนาองค์กรอย่างมั่นคง PGM ให้ความสำคัญกับการลงทุนด้านความรับผิดชอบต่อสังคมขององค์กรในระยะยาวมาโดยตลอด ในช่วง สามปีข้างหน้า PGM จะบูรณาการกิจกรรมด้านสาธารณประโยชน์และการกุศลเข้าเป็นส่วนหนึ่งของระบบการพัฒนาองค์กรในระยะยาว เพื่อคืนกลับสู่สังคมผ่านแนวทางที่ ต่อเนื่อง เป็นรูปธรรม และสามารถดำเนินการได้จริง เมื่อเดือนที่ผ่านมา PGM ได้ตอบสนองต่อสถานการณ์อุทกภัยในพื้นที่จังหวัดสงขลาอย่างเร่งด่วน โดยจัดทีมงานลงพื้นที่ประสบภัยเพื่อให้ความช่วยเหลือแก่ประชาชนที่ได้รับผลกระทบ ทิศทางหลักของกิจกรรมสาธารณประโยชน์ การดูแลชุมชน: ดำเนินกิจกรรมช่วยเหลือชุมชนระดับฐานรากอย่างสม่ำเสมอ พร้อมการมอบสิ่งของอุปโภคบริโภคที่จำเป็น การสนับสนุนด้านการศึกษา: ให้ความสำคัญกับโอกาสทางการศึกษาและสภาพแวดล้อมในการเติบโตของเยาวชนและกลุ่มผู้ด้อยโอกาส การมีส่วนร่วมของพนักงาน: ส่งเสริมให้พนักงานและทีมงานเข้าร่วมกิจกรรมสาธารณประโยชน์ร่วมกัน เพื่อสร้างวัฒนธรรมองค์กรเชิงบวก PGM เชื่อมั่นว่า องค์กรที่ยั่งยืนอย่างแท้จริง ไม่เพียงสร้างคุณค่าทางเศรษฐกิจเท่านั้น แต่ยังต้องสร้างคุณค่าทางสังคมอย่างต่อเนื่องควบคู่กันไป PGM ดำเนินกิจกรรมเพื่อสังคมในระดับชุมชนอย่างต่อเนื่อง และปฏิบัติความรับผิดชอบต่อสังคมขององค์กรอย่างจริงจัง โดยให้ความสำคัญกับการพัฒนาด้านการศึกษา และสนับสนุนการเติบโตของเยาวชนผ่านการลงมือปฏิบัติจริง การมีส่วนร่วมของพนักงานในกิจกรรมสาธารณประโยชน์ได้กลายเป็นส่วนสำคัญของวัฒนธรรมองค์กรของ PGM สำหรับ PGM กิจกรรมสาธารณประโยชน์ไม่ใช่การดำเนินการเพียงครั้งเดียว แต่เป็นแนวคิดการพัฒนาที่องค์กรยึดมั่นและดำเนินการอย่างต่อเนื่องในระยะยาว 6. มองสู่อนาคต: ก้าวเดินอย่างมั่นคง เพื่อความก้าวหน้าอย่างยั่งยืน PGM ระบุว่า ช่วงปี 2026–2028 ถือเป็นระยะสำคัญที่บริษัทจะก้าวจาก การพัฒนาอย่างมั่นคง ไปสู่ ความเป็นองค์กรที่มีระบบและโครงสร้างสมบูรณ์ โดย PGM จะยึดมั่นในหลักการพัฒนาอย่าง ถูกต้องตามกฎหมาย โปร่งใส และมั่นคง พร้อมเติบโตร่วมกับพนักงาน พันธมิตรทางธุรกิจ และตลาดอย่างยั่งยืน PGM เชื่อมั่นว่า ก้าวอย่างมั่นคง จึงจะไปได้ไกล และมีเพียงแนวคิดการพัฒนาในระยะยาวเท่านั้น ที่สามารถสร้างคุณค่าที่แท้จริงได้   Contact: Daniel Thomas Email: pinnacleglobalmedia@gmail.com Website: www.pgmpy.com

With Long-Term Vision as its Core, PGM Embarks on a New Phase of High-Quality and Regionalized Development Recently, PGM officially released its 2026 development strategy and 2027-2028 mid-to-long-term development plan. Against the backdrop of a deepening global digital economy and evolving organizational structures, PGM will adhere to the core development philosophy of "stability, compliance, and long-term vision," comprehensively promoting organizational upgrades, system improvements, and regionalized development to lay a solid foundation for sustained growth in the coming years. PGM stated that this plan is not aimed at short-term expansion, but rather at long-term sustainable development, striving to build a mature platform system with a clear structure, stable operation, and replicability. I. 2026 Development Strategy: Strengthening the Foundation and Improving Quality 2026 will be considered a "critical year for strengthening the foundation" for PGM's development. The company will steadily advance around the following four strategic priorities: (I) Upgrading the Organizational System and Enhancing Management Capabilities PGM will continue to optimize its organizational structure and job division, improve promotion channels and management training systems, and focus on enhancing the comprehensive capabilities of middle and senior management personnel to create a more stable and sustainable team structure. (II) Comprehensively Strengthening Compliance and Risk Control Systems In terms of compliant operations, PGM will further enhance financial transparency, internal audit mechanisms, and system risk control capabilities, continuously strengthen data security and account management, and clarify and consolidate its market positioning of "formal positions, compliant operations, and long-term development." (III) Upgrading System and Technology Capabilities PGM plans to complete several system upgrades in 2026, including automated operational processes, optimized data statistics and performance settlement, providing a stable and efficient technical foundation for subsequent large-scale and cross-regional development. (iv) Brand building and positive market communication By unifying external information messaging and strengthening communication through mainstream media and social media platforms, PGM will further enhance its brand credibility and establish a "stable, professional, and trustworthy" corporate image. II. 2027-2028 Mid-to-Long-Term Plan: Deepening Development in Southeast Asia, Promoting Scale and Regionalization in Parallel After consolidating its system in 2026, PGM will officially enter a phase of accelerated scale and regionalization development centered on Southeast Asia in 2027-2028. The company will focus on the Southeast Asian market, particularly Thailand and Myanmar, steadily advancing regional expansion based on a mature operating model. 2027: Steady Scale Development Continue to expand team size in mature markets Cultivate more local leaders with independent management and replication capabilities Improve overall operational efficiency, personnel efficiency, and team stability 2028: Promoting Regionalization and Collaborative Development Gradually promote regional replication based on a mature operating model Build cross-regional management and collaboration mechanisms Create a multi-regional operating system with long-term viability PGM stated that regionalization development will be based on the premise of "steady progress and controllable risks," ensuring that each step of expansion is built upon a mature system. III. Accelerating Localization in Thailand: The Advertising and Recruitment System is Being Implemented at an Accelerated Pace With the increasing number of partnerships with local Thai brands, the platform's needs for advertising integration and business coordination are becoming increasingly clear. Based on this trend, PGM is steadily advancing its plan to establish an advertising and recruitment department in its Thailand branch, prioritizing initial setup in a Bangkok office building. Currently, the relevant arrangements are in the preparatory stage, including: office environment planning, staffing assessment, and optimization of the integration of advertising business processes with the platform system. If the overall progress is smooth, it is expected that the advertising and recruitment department will be ready for onboarding and trial operation within approximately one month, enabling more efficient integration with local Thai brands and partner resources. The company will steadily refine subsequent plans based on actual progress and make preliminary preparations for the future construction and occupancy of PGM's Thailand branch's independent office building. PGM consistently adheres to the development principles of "planning first, then implementation, long-term focus, and stability," ensuring that every step of its strategic deployment has sustainable value. IV. A People-Centric Long-Term Development Philosophy PGM firmly believes that the long-term growth of its employees is the company's most important competitive advantage. Over the next three years, the company will continue to invest resources in management talent development, the establishment of long-term incentive mechanisms, and the design of diversified revenue structures to provide employees with clearer and more predictable career development paths, achieving a virtuous cycle of personal growth and platform development. V. Fulfilling Social Responsibility: Giving Back to Society Through Long-Term Philanthropy While steadily advancing its corporate development, PGM has always prioritized long-term investment in corporate social responsibility. Over the next three years, PGM will integrate philanthropic and charitable activities into its long-term development system, giving back to society through sustainable and practical means. Last month, PGM responded proactively to the floods in Songkhla, Thailand, and organized a team to provide assistance to the affected people. Key Areas of Philanthropic Action Community Care: Providing regular assistance and donations of essential goods to grassroots communities. Educational Support: Focusing on learning opportunities and growth environments for youth and vulnerable groups. Employee Philanthropic Participation: Encouraging employees and teams to participate in philanthropic activities, fostering a positive corporate culture. PGM believes that a truly sustainable company should not only create economic value but also continuously create social value. PGM continuously engages in community service initiatives, actively fulfilling its corporate social responsibility. It focuses on educational development and supports the growth of young people through concrete actions. Employee participation in public welfare projects has become an important part of PGM's corporate culture. Public welfare is not a one-off act, but a long-term development philosophy that PGM adheres to. VI. Looking to the Future: Steady Progress for Sustainable Development PGM stated that 2026–2028 is a crucial period for the company, marking its transition from "steady development" to "system maturity." PGM will adhere to the principles of compliance, transparency, and steady growth, growing together with its employees, partners, and the market. PGM believes: Only by moving steadily can we go far; only through long-termism can we create true value. Contact: Daniel Thomas Email: pinnacleglobalmedia@gmail.com Website: www.pgmpy.com

New York, NY – December 26, 2025 – (SeaPRwire) – Taxinexo, a U.S.-based autonomous vehicle operator, has entered a new phase of large-scale commercial deployment after nearly five years of continuous operation in the United States. Leveraging its mature Level 4 autonomous driving technology and proven operational capabilities, the company has expanded multi-scenario services across several U.S. states, positioning itself as a representative case of how federal and state policy coordination is accelerating the commercialization of autonomous driving in the U.S. smart mobility sector. Since its inception, Taxinexo’s growth trajectory has been deeply intertwined with the US autonomous driving industry’s policy support system. The US federal government, through national strategic documents such as the Comprehensive Autonomous Vehicle Initiative, has established a development orientation of “safety first, encouraging innovation,” providing companies with a flexible regulatory environment—including simplified administrative exemption procedures for autonomous vehicles, allowing steering wheel-less and pedal-less vehicles that meet technical standards to be tested and operated on public roads, significantly lowering the policy threshold for companies to iterate their technology. Meanwhile, the Inflation Reduction Act’s tax credit of up to $7,500 per vehicle for Level 3 and above autonomous driving vehicles further assisted Taxinexo in completing its R&D investment and fleet expansion, enabling it to achieve large-scale commercial operation in multiple states across the US. This has allowed it to accumulate millions of kilometers of real-world road operation data and build an operational network covering diverse scenarios such as urban main roads, business parks, and commuter shuttles. In an interview with this newspaper, Taxinexo’s Global Marketing Head stated, “The policy support in the US over the past five years has provided us with an excellent development platform. From technology R&D to commercialization, the flexible regulatory environment and precise policy support have allowed us to accumulate core capabilities to handle complex scenarios. In the future, we will continue to leverage local policy advantages, deepen our diversified scenario operation layout, and help promote the US autonomous driving industry towards a more efficient and safer stage.” Data shows that the US autonomous driving industry is rapidly expanding, with leading companies continuously increasing their fleet sizes and weekly order volume exceeding hundreds of thousands, indicating a broad commercial prospect for the industry. Taxinexo reportedly plans to further expand its service coverage in the United States based on its existing operations, focusing on high-frequency travel scenarios such as airport shuttles and intercity commuting, and will continue to increase investment in technology research and development to promote the iterative upgrade of its autonomous driving system. In the future, its large-scale operational experience may provide a replicable practice model for the intelligent transportation upgrades of more cities in the United States. Social Links Telegram: https://t.me/taxinexo X: https://x.com/taxinexo Facebook: https://www.facebook.com/profile.php?id=61585301312596 Instagram: https://www.instagram.com/taxinexo LinkedIn: https://www.linkedin.com/company/taxinexo/ YouTube: https://www.youtube.com/@taxinexo Media contact Brand: Taxinexo Contact: Media team Email: support@taxinexo.com Website: https://www.taxinexo.com

The King of the Monsters Becomes a Cinematic Welcome and Farewell, Showcasing Japanese Entertainment to Millions of International Travelers at Japan’s Global Gateway Singapore – December 23, 2025 – (SeaPRwire) – The HANEDA GODZILLA GLOBAL PROJECT officially launched a mega-scale initiative to broadcast Japanese entertainment to the world from Haneda Airport, through the collaboration of three companies: Toho Co., Ltd., Japan Airport Terminal Co., Ltd., and Tokyo International Airport Terminal Corporation. Under the theme “Godzilla welcomes all visitors to Japan and sees them off as they depart,” a colossal Godzilla statue, approximately 40 meters long and 9 meters tall, has been revealed inside Japan’s international gateway at Haneda Airport Terminal 3. Modeled after the original Godzilla, the monument surpasses the size of existing indoor installations and is designed to be viewed from multiple angles throughout Terminal 3. Additional installations in the area include Godzilla: The Great Monster Advance Picture Scroll in the arrival lobby and a standing statue from Godzilla Minus One that will be installed on December 3, further expanding the presence of the popular monster across arrivals and departures. To commemorate the completion of the world’s largest indoor Godzilla monument, a special announcement event was held at Haneda Airport, featuring remarks from notable guests. This consisted of Keiji Ota, Senior Managing Executive Officer and Chief Godzilla Officer (CGO) of Toho Co., Ltd.; Masatoshi Akahori, President and Representative Director of Tokyo International Air Terminal Corporation; and special guest actress Riko Fukumoto, ambassador for the “Godzilla The Ride” attraction at Seibuen Amusement Park. All of the guest speakers reflected on the cultural significance of the six-year project and Godzilla’s role as a global symbol of Japanese entertainment. As travel ramps up for the new year, the HANEDA GODZILLA GLOBAL PROJECT is set to leave a lasting impression on millions of international travelers passing through Terminal 3 with an encounter with one of Japan’s most iconic cultural symbols. The completion announcement event was held on Friday, December 19, with public installations opening in conjunction with year-end and New Year travel, and additional displays debuting beginning December 23. The unveiling was held at Haneda Airport Terminal 3 in Tokyo, Japan spanning both the departure and arrival lobbies at Japan’s primary international gateway. About TOHO Co., Ltd. TOHO Co., Ltd. is a leading Japanese entertainment company founded in 1932.  Its four main business pillars are the cinema business, which includes production, distribution and exhibition; the theatrical business, which includes production and exhibition; the anime business, which has been expanding globally in recent years; and the real estate business, which focuses on development in urban areas. TOHO’s worldwide acclaimed works include theatrical films such as the “Godzilla” series and “Seven Samurai” directed by Akira Kurosawa, and TV anime series such as “My Hero Academia” and “Jujutsu Kaisen”. These anime series are produced and distributed through the TOHO animation label, and are delivered to a wide range of audiences around the world. Media Contact TOHO Entertainment Asia hello@tohoea.com.sg

New York, NY – December 23, 2025 – (SeaPRwire) – Holiverse, a biotech platform, has begun active development of a decentralized AI device designed to operate entirely offline without cloud dependency. The device will embed private artificial intelligence directly on hardware, eliminating the need to transmit personal data to external servers. According to the company, this approach addresses growing concerns about data sovereignty, privacy erosion and the concentration of AI processing power in centralized platforms. “We have conflated intelligence with centralization,” said Lado Okhotnikov, founder of Holiverse. “We built these vast, brilliant minds and asked them to solve our problems. But in doing so, we outsourced our sovereignty.” The Holiverse decentralized AI initiative targets three key capabilities: On-device processing: All data remains in a closed loop on the user’s hardware Offline functionality: Intelligence operates without internet connectivity Hyper-personalization: Models tuned to individual biological and behavioral data “This is undoubtedly a complex and resource-intensive process, and we are engaging some of the leading AI specialists,” Okhotnikov added. “This technology has the potential to significantly reduce the risks associated with AI and make interaction with it truly personal.” Holiverse expects to present initial developments publicly in the coming months. About Holiverse Holiverse is a biotech platform that integrates human biology and advanced technology. Founded by Lado Okhotnikov, the company creates holistic health solutions through personalized, data-driven approaches. Learn more at holiverse.ai. Social Links X: https://x.com/Holiverse Telegram: https://t.me/holiverse_ENG Media Contact Brand: Holiverse Contact: Media team Email: mailbox@holiverse.ai Website: https://holiverse.ai

Seoul, Korea – December 23, 2025 – (SeaPRwire) – HTM Korea, a Korean fire-safety technology company, announced the global expansion of its innovative automatic fire-suppression product line, CERA+, designed to prevent electrical fires in outlets and distribution boards. The company has rapidly grown within the domestic market through public procurement channels, supplying products to government agencies, educational institutions, and major industrial clients. CERA+ is a compact fire-suppression patch that activates automatically when an electrical hotspot occurs. Containing a certified clean-agent extinguishing compound, the patch bursts at a specific temperature and releases the agent to suppress flames at the earliest stage. The product has received official KFI (Korea Fire Institute) type approval, along with reliability tests such as temperature, humidity, and durability evaluations. HTM Korea currently offers outlet-type patches and distribution-board models in 20L, 40L, and 80L capacities. The company is accelerating its entry into Southeast Asia, the Middle East, and the United States, supported by growing demand from data centers, residential complexes, and industrial facilities. “As electrical fire risks continue to rise worldwide, we aim to provide simple but highly effective protection that any facility can adopt easily,” said a company representative. “We will continue expanding our product line and strengthening global partnerships.” Media contact Company: HTM Korea Co., Ltd. Contact: Su Hyeon Oh Phone: +82-10-3504-2913 Email: cera@cera.krWebsite: https://www.cera.kr